Pubblicazioni 1999-2000
Pubblicazioni 2001-2002
Pubblicazioni 2003-2004
Pubblicazioni 2005-2007

Elenco delle pubblicazioni dal 1999 ad oggi

1. Rimoli, M.G.; Avallone, L.; de Caprariis, P.: Galeone, A.; Forni, F.; Vandelli, M.A. Synthesis and characterisation of poly(d,l-lactic acid)-idoxuridine conjugate. J. Controlled Release 1999, 58, 61-68.

2. Mucci, A.; Schenetti, L.; Vandelli, M.A.; Ruozi, B.; Forni, F. Evidence of the existence of 2:1 guest-host complexes between diclofenac and cyclodextrins in D2O solutions. A 1H and 13C NMR study on diclofenac/b-cyclodextrin and diclofenac/2-hydroxypropyl-b-cyclodextrin systems J. Chem. Res. (M) 1999, 1761-1795. J. Chem. Res. (S) 1999, 414-415.

3. Rojas, J.; Pinto-Alphandary, H.; Leo, E.; Pecquet, S.; Couvreur, P.; Gulik, A.; Fattal, E. A polysorbate-based non-ionic surfactant can modulate loading and release of b-lactoglobulin entrapped in multiphase poly (DL-lactide-co-glicolide) microspheres. Pharm. Res., 1999, 16, 355-360.

4. Leo, E.; Cameroni, R.; Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates.Int. J. Pharm. 1999, 180, 23-30.

5. Rustichelli, C.; Gamberini, M.C.; Ferioli, V.; Gamberini, C. Properties of the racemic species of verapamil hydrochloride and gallopamil hydrochloride. Int. J, Pharm., 1999, 23, 111-120.

6. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: aldose reductase inhibitors and other approaches. Med. Res. Rev., 1999, 19,3-23.

7. Costantino, L.; Rastelli, G.; Gamberini, M.C.; Vinson, J.A.; Bose, P.; Iannone, A.; Staffieri, M.C; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-benzopyran-4-ones antioxidants as aldose reductase inhibitors. J. Med. Chem., 1999, 42, 1881-1893.

8. Costantino, L.; Rastelli, G.; Gamberini, M.C.; Giovannoni, M.P.; Dal Piaz, V.; Vianello, P.; Barlocco, D. Isoxazolo[3,4-d]-pyridazin-7-(6H)-ones as a potential substrate for new aldose reductase inhibitors. J. Med. Chem. 1999, 42, 1894-1900.

9. Rojas, J.; Pinto-Alphandary, H.; Leo, E.; Pecquet, S.; Couvreur, P.; Fattal, E. Optimization and encapsulation release of b-lactoglobulin entrapped poly(dL-lactide-co-glicolide) microspheres. Int. J. Pharm, 1999, 183, 67–71.

10. Tolle, S.; Caudron, E.; Leo, E.; Couvreur, P.; Andrmont, A.; Fattal, E. In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin. Int. J. Pharm, 1999, 183, 73–79.

11. Leo, E.; Forni, F.;. Bernabei, M. T. Surface drug removal from ibuprofen-loaded PLA microspheres. Int. J. Pharm., 2000, 196, 1-9.

12. Pecquet, S.; Leo, E.; Fritsche, R.; Pfeifer, A.; Couvreur, P.; Fattal. E. Oral tolerance elicited in mice by b-lactoglobulin entrapped in biodegradable microspheres. Vaccine, 2000, 18, 1196-1202.

13. Vandelli, M. A.; Ruozi, B.; Forni, F. PLA microparticles for nimesulide prolonged release: effect of the preparative variables. S.T.P Pharma Sciences, 1999, 9, 567-572.

14. Rastelli, G.; Antolini, L.; Benvenuti, S.; Costantino, L. Structural bases for the inhibition of Aldose reductase by phenolic compounds. Bioorg. Med. Chem., 2000, 8, 1151-1158.

15. Costantino, L.; Rastelli, G.; Gamberini, M.C.; Barlocco, D. Pharmacological approaches to the treatment of diabetic complications. Exp. Opin. Ther. Patents, 2000, 10, 1245-1262.

16. Rakowitz, D.; Heinisch, G.; Lukavsky, P.; Kiendler, S.; Trenkwalder, C.; Barlocco, D.; Rastelli, G.; Costantino, L. A series of diarylsubstituted oximes as potential substrate for new aldose reductase inhibitors. J. Heterocyclic Chem., 2000, 1089-1096.

17. Del Corso, A.; Costantino, L.; Rastelli, G.; Buono, F.; Mura, U. Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. Exp. Eye Res., 2000, 71, 515-521.

18. Glennon, R.A.; Dukat, M.; Grella, B.; Hong, S.S.; Costantino, L.; Teitler, M.; Smith, C.; Egan, C.; Davis, K.; Mattson, M.V. Binding of beta-carbolines and related agents at serotonin (5-HT-2 and 5-HT-1A), dopamine (D-2) and benzodiazepine receptors. Drug and Alcohol Dependence, 2000, 60, 121-132.

19. Rustichelli, C.; Gamberini, G.; Ferioli, V.; Gamberini, M.C.; Ficarra, R.; Tommasini, S. Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biomed. Anal., 2000, 23, 41-54.

20. Ficarra, R; Ficarra, P.; Di Bella, M.R.; Raneri, D.; Tommasini, S.; Calabrò, M.L.; Gamberini, M.C.; Rustichelli, C. Study of b-blockers/b-cyclodextrins inclusion complex by NMR; DSC; X-ray and SEM investigation. J. Pharm. Biomed. Anal., 2000, 23, 33-40.

21. Ferioli, V.; Rustichelli, C.; Pavesi, G.; Gamberini, G. Analytical characterisation of hashish samples. Chromatographia, 2000, 52; 39-44.

22. Costantino, L.; Rastelli, G.; Cignarella, G.; Barlocco, D. Synthesis and aldose reductase inhibitory activity of a new series of benzo[h]cinnolinone derivatives. Il Farmaco, 2000, 55, 544-552.

Vandelli, M.A.; Ruozi, B.; Forni, F.; Mucci, A.; Salvioli, G.; Galli, E. A solution and solid state study on 2-hydroxypropyl-b-cyclodextrin complexation with hyodeoxycholic acid. J. Incl. Phenom., 2000, 37, 237-251.

24. Ventura, P.; Panini, R.; Montosi, G.; Garuti, C.; Vandelli, M.A.; Brunetti, G.; Tauschel, H-D.; Pietrangelo, A.; Salvioli, G. Ursodeoxycholic acid complexation with 2-hydroxypropyl-b-cyclodextrin increases ursodeoxycholic acid biliary excretion after single oral administration in rats. Pharmacology, 2001, 62, 107-112.

25. Mucci, A.; Schenetti, L.; Vandelli, M.A.; Ruozi, B.; Salvioli, G.; Forni, F. Comparison between Roesy and 13C NMR complexation shifts in deriving the geometry of inclusion compounds: a study on the interaction between hyodeoxycholic acid and 2-hydroxypropyl-b-cyclodextrin. Supramolecular Chem., 2001, 12, 427-433.

Vandelli, M.A.; Rivasi, F.; Guerra, P.; Forni, F.; Arletti, R. Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies. Int. J. Pharm., 2001, 215, 175-184.

27. Vandelli, M.A.; Sergi, S.; Ruozi, B.; Forni, F. Preformulative and formulative studies on inclusion complexes between cyclodextrins ursodeoxycholic acid. S.T.P. Pharma, 2001, 11, 157-165.

28. Pignatello, R.; Ferro, M., De Guidi, G.; Salemi, G.; Vandelli, M.A.; Guccione, S.; Geppi, M.; Forte, C.; Puglisi, G. Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS 100 and RL100. Int. J. Pharm., 2001, 218, 27-42.

29. Del Piaz, A.; Scatturin, A.; Pavan, B.; Biondi, C.; Vandelli, M.A.; Forni, F. Poly(lactic acid) microspheres for the sustained release of a selective A1 receptor agonist. J. Controlled Release, 2001, 73, 303-313.

Costantino, L.; Del Corso, A.; Rastelli, G.; Petrash, J.M.; Mura, U. 7-hydroxy-2-substituted-4H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study. Eur. J. Med. Chem., 2001, 36, 697-703.

Rustichelli, C.; Ferioli, V.; Gamberini, G.; Stancanelli, R. Enantiomeric separation of local anaesthetic drug by HPLC on chiral stationary phases. Chromatographia, 2001, 54, 731-736.

32. Ferioli, V.; Rustichelli, C.; Pavesi, G.; Gamberini, G. New combined treatment of hypermelanosis: analytical studies on efficacy and stability improvement. Int. J. Cosm. Sci., 2001, 23, 333-340.

33. Del Piaz, A.; Scatturin, A., Pavan, B., Biondi, C., Vandelli, M.A.. Forni, F. Poly(lactic acid) microspheres for the sustained release of antiischemic agents. Int. J. Pharm., 2002, 242, 157-165.

34. Rakowitz, D.; Matuszczak, B.; Gritsch, S. Hofbauer, P.; Krassnigg, A.; Costantino, L. On the prodrug-potential of novel Aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure. Eur. J. Pharm. Sci., 2002, 15, 11-20.

35. Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Niolò F, Ottanà R, Vigorita MG. Synthesis and Aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. 2002, 10, 1077-1084.

Rastelli G, Costantino L., Gamberini MC, Del Corso A, Mura U, Petrash JM, Ferrari AM, Pacchioni S. Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study. Bioorg. Med. Chem., 2002, 10, 1427-1433.

37. Ficarra, R.; Tommasini, S.; Raneri, D.; Calabrò, M.L.; Di Bella, M.R.; Rustichelli, C.; Gamberini, M.C.; Ficarra, P. Study of flavonoids/b-cyclodextrins inclusion complexes by NMR; FT-IR; DSC; X-ray investigation. J. Pharm. Biomed. Anal., 2002, 29, 1005-1014.

38. Rastelli G, Ferrari AM, Costantino L, Gamberini MC. Discovery of new inhibitors of aldose reductase from molecular docking and database screening. Bioorg. Med. Chem., 2002, 10, 1437-1443.

39. Costantino L., Ferrari AM., Gamberini MC, Rastelli G. Nitrophenyl Derivatives as Aldose Reductase Inhibitors. Bioorg. Med. Chem., 2002, 10, 3923-3932.

Costantino L., Raimondi L., Pirisino, R.; Brunetti T.; Pessotto P., Giannessi F., Lins A.P., Barlocco D., Antolini L., El-Abady S. Isolation and Pharmacological Activities of the Tecoma stans Alkaloids. Il Farmaco, 2003, 58, 781-785.

Costantino L., Lins A.P., Barlocco D., Celotti F.; El-Abady S., Brunetti T., Maggi R., Antolini l. Characterization and Pharmacological Actions of Tecostanine, an Alkaloid of Tecoma stans. Pharmazie, 2003, 58, 140-142.

Giannavola, C.; Bucolo, C.; Maltese, A.; Paolino, D.; Vandelli, M.A.; Puglisi, G.; Lee, V.H.L.; Fresta, M. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res., 2003, 20, 584-590.
43. Ruozi, B.; Forni, F.; Battini, R.; Vandelli, M.A. Cationic liposomes for gene transfection. J. Drug Targeting, 11, 407-414; 2003.

44. Rustichelli, C.; Gamberini, M.C.; Ferioli, V.; Gamberini, G. Enantioselective analyses of antihistaminic drugs by high performance liquid chromatography. Chromatographia.

Gamberini, M.C.; Ferioli, V.; Baraldi, P.; Baraldi, C.; Gamberini, G.; Rustichelli, C. Raman Spectroscopy applied on pharmaceutical polymorphs: Chloramphenicol palmitate. J. Raman Spectr.

46. M.A. Vandelli, M. Romagnoli, A. Monti, M. Gozzi, P Guerra, F. Rivasi, F. Forni. Microwave treated gelatin microspheres as drug delivery system. J. Controlled Release, 2004, 96, 67-84;

R. Pignatello D. Spadaro, M.A. Vandelli, F. Forni, G. Puglisi. Characterization of the mechanism of interaction in ibuprofen-Eudragit RL100 coevaporates. Drug Develop. Ind. Pharm., 2004.

48. E. Leo, B. Brina, F. Forni, M.A. Vandelli. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int. J. Pharm. 2004, 278 (1) , 133-141.

49. Tosi G., Zironi F., Caselli E., Forni A., Prati F., Biocatalityc asymmetric syntesis of (S) and (R) Timolol, Synthesis, 2004, 10, 1625-1628.

Caselli E., Tosi G., Forni A., Bucciarelli M. and Prati F. Chemo-enzymatic synthesis of levodropropizine Il Farmaco, 2003, 58, 10, 2003,1029-1032.

51. A. Dalpiaz, E. Leo, F. Vitali, B. Pavan, A. Scatturin, F. Bortolotti, S. Manfredini, E. Durini, F. Forni, B. Brina, M.A. Vandelli. Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives. Biomaterials, 2005, 26, 11, 1299-1306.

52. Tosi G., Rivasi F., Gandolfi F., Costantino L., Vandelli M.A. and Forni F. Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles, Biomaterials, 2005, 26, 19, 4189-4195.

53. B.Ruozi, G. Tosi, F. Forni, M. Fresta, M. A. Vandelli, Atomic Force Microscopy and Photon Correlation Spectroscopy: Two Techniques for Rapid Characterization of Liposomes, Eur. J. Pharm. Sci., 2005, 25, 81-89.

54. F.Rivasi, G.Tosi, B.Ruozi, C.Curatola, Vegetable cells in cervico vaginal smears, 2006, Diagnostic Cytopathology, 34,  45-49.

55. B.Ruozi, G. Tosi, F. Forni, M. A. Vandelli, Ketorolac tromethamine liposomes: encapsulation and release studies, 2005, Journal of Liposome Research, 15,  175-185.

56. B. Ruozi, R. Battini, G. Tosi, F. Forni, M. A. Vandelli Liposome-Oligonucleotides interaction for in vitro uptake by COS I and HaCaT cells, 2005, Journal of Drug Targeting, 13, 295-304.

57. L. Costantino, F. Gandolfi, G. Tosi, F. Rivasi, M. A. Vandelli, F. Forni, Peptide-Derivatized Biodegradable Nanoparticles Able to Cross the Blood Brain Barrier, 2005, Journal of Controlled Release, 2005, 108(1), 84-96.

58.E. Leo, C. Contado, F. Bortolotti, B. Pavan, A. Scatturin, G. Tosi, S. Manfredini, A. Angusti e A. Dalpiaz, Nanoparticle formulation aspects may affect the stabilization of an antiischemic prodrug, International Journal of Pharmaceutics, 2006, 307, 103-113.

59. E. Leo, B. Ruozi, G. Tosi e M.A. Vandelli, PLA-microparticles formulated by means a thermoreversible gel able to modify protein encapsulation and release without being co-encapsulated, International Journal of Pharmaceutics, Accepted, 2006.

60. L. Costantino, F. Gandolfi, L. Bossy-Nobs, G. Tosi, R. Gurny, F.Rivasi, M.A. Vandelli and F. Forni, Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures, Biomaterials, 27(26), 2006, 4635-4645.

61. E.Leo, B. Ruozi, G. Tosi,  M.A. Vandelli, PLA-microparticles formulated by means a thermoreversible gel able to modify protein encapsulation and release without being co-encapsulated, International Journal of Pharmaceutics, 2006, 323, 131-138.

62. B. Ruozi, G. Tosi, E. Leo, B. Parma, S.Vismara, F.Forni and M.A. Vandelli, Intact collagen and atelocollagen sponges: characterization and ESEM observation, Materials Science and Engineering C, 2006,  doi:10.1016/j.msec.2006.08.018 .ů

63. T. Musumeci, C.A. Ventura, I. Giannone, B. Ruozi, L. Montenegro, R. Pignatello and G. Puglisi PLA/PLGA nanoparticles for sustained release of docetaxel, International Journal of Pharmaceutics, 2006, 325, 1-2, 172-179.

64. B. Ruozi, R. Battini, M. Montanari, A. Mucci, G. Tosi, F. Forni, M.A. Vandelli, DOTAP-UDCA vesicles: novel approach in ODN delivery, Nanomedicine, Nanotechnology, Biology and Medicine, accepted for publication.

65. A.Dalpiaz, C. Contado, E. Vighi, G. Tosi, E.Leo, Preparation and characterization of particulate drug delivery systems for the brain targeting, in “ Handbook of Particulate Drug Delivery”, American Scientific Publishers, USA, 2006.

66. G. Tosi, L.Costantino, F. Gandolfi, B. Ruozi, F. Rivasi, M. A. Vandelli, F.Forni, Nanoparticelle per il direzionamento cerebrale di farmaci, Notiziario Chimico Farmaceutico, 98-100, Aprile 2006.

67. B. Ruozi, G.Tosi, E. Leo, M. A.Vandelli, Application of atomic force microscopy to characterize liposomes as drug and gene carriers, Talanta, Accepted for publication.

68. B.Ruozi, R. Battini, M.Montanari, A.Mucci, G.Tosi, F. Forni, M.A. Vandelli, Dotap/Udca vesicles: novel approach in ODN delivery, Nanomedicine:Nanotechnology, Biology and Medicine, 2007, 3(1), 1-13.

69. E. Vighi, B. Ruozi, M. Montanari, R. Battini, E. Leo, Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid, European Journal of Pharmaceutics and Biopharmaceutics, 2007, accepted for pubblication, DOI: 10.1016/j.ejpb.2007.02.006.